PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:		(11) International Publication Number: WO 93/0416
C12N 5/00	A1	43) International Publication Date: 4 March 1993 (04.03.93
(21) International Application Number: PCT/US (22) International Filing Date: 28 August 1991		545 Middlefield Road, Suite 200, Menlo Park, CA 9402
(30) Priority data: 748,471 26 August 1991 (26.08.91)	(81) Designated States: AU, CA, JP, KR, European patent (AT BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE)
 (71) Applicant: THE STATE OF OREGON acting through THE STATE OF BOARD OF HIGHI CATION on behalf of THE OREGON I SCIENCES UNIVERSITY [US/US]; 3181 S Jackson Park Road, L-335, Portland, OR 9720 (72) Inventors: SHIPLEY, Gary, D.; 1805 N.W. 143rd A-15, Portland, OR 97229 (US). COOK, Pa 10919 N.W. 29th Avenue, Vancouver, WA 9868 	ÉR ED HEALT S.W. Sa I (US). d Aven tul, W.	With international search report.
•		

(57) Abstract

Human epithelial cells are cultured in protein-free standard media to produce autocrine- and paracrine-acting growth factors. The resulting mixture of human keratinocyte-derived conditioned medium factors (kdCMF) is useful to promote healing of surface wounds, ulcerations and other hypoproliferative skin pathologies.

8/19/2007, EAST Version: 2.1.0.14

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	, FI	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gahon	MW	Malawi
BE	Belgium .	CB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO	Norway
BC	Bulgaria	CR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL.	Poland
BR	Brazil .	ΙE	Ireland	PT	Portugut
CA	Canada	ıΤ	ltaly	RO	Romania -
CF	Central African Republic	JP	Japan	RU	Russian Federation
CC	Congo	KP	Democratic People's Republic	SD	Sudan
CH	Switzerland		of Korga	SE	Sweden ·
CI	Côte d'Ivoire	KR	Republic of Korea	SK	Sluvak Republic
CM'	Cameroon	LI	Licehtenstein	SN	Senegal
cs	Czechoslovakia	LK	Sri Lanka	รบ	· Soviet Union
CZ	Czech Republic	່ເບ	Luxembourg	TD	Chad
DE	Germany	MC	Monaco	TC	Togo
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	МІ	Mali	US	United States of America

8/19/2007, EAST Version: 2.1.0.14

KER

AS A SOURCE OF GROWTH FACTORS

Technical Field

This invention is in the general field of wound healing. More specifically it relates to a novel method of producing human keratinocyte-derived conditioned medium factors (kdCMF) which promote healing of surface wounds, ulcerations, and other hypoproliferative skin conditions.

15

20

25

30

35

5

Background of the Invention

The growth of cells may be regulated by both autocrine and paracrine growth factors. Autocrine growth factors are those secreted by growing cells which factors stimulate or inhibit the proliferation of the same cell. Paracrine growth factors are those that act on neighboring cells.

It was originally believed that the growth of normal cells was controlled by paracrine factors while the growth of malignant cells was promoted by autocrine factors. More recently, exceptions to these generalizations have become evident as autocrine growth factors have been implicated in the normal regulation of cell proliferation during growth, development and wound repair (Clark and Henson (eds), The Molecular and Cellular Biology of Wound Repair (1988); Barbul et al. (eds) Progress in Clinical and Biological Research (1987), Vol. 266. Indeed, it has been shown by the inventors herein that normal keratinocytes can be cultured in a growth factor-free medium in vitro

10

15

20

25

30

35

(Shipley, G. et al., <u>J Cell Physiol</u> (1989) <u>138</u>:511-518; Cook, P. et al., <u>J Cell Physiol</u> (1991) <u>146</u>:277-289).

Studies have suggested that neonatal human keratinocytes produce autocrine- or paracrine-acting growth factors in vitro (Gilchrest et al., J Cell Physiol (1983) 117:235-240; Cook et al., <u>J Cell Physiol</u> (1991) 146:277-289). More specifically, it has been shown that human keratinocyte cultures produce TGFα (Coffey et al., Nature (1987) 328:817-820; Pittelkow et al., J Biol Chem (1989) 264:5164-5171; Cook et al., Mol Endocrin (1990) 4:1377-1385), keratinocyte-derived autocrine factor (KAF)/amphiregulin (AR) (Cook et al., Mol Cell Biol (1991) 11:2547-2557, TGFβ (Shipley et al., Cancer Res (1986) 46:2068-2071) and bFGF (Cook et al., Mol Endocrin (1990) 4:1377-1385). Other investigators have also demonstrated that human keratinocytes produce bFGF (Halaban et al., <u>J Cell Biol</u> (1988) <u>107</u>:1611-1619), PDGF (Ansel et al., J Invest Dermatol (1990) 94:101s-107s) and interleukins (Blanton et al., Proc Natl Acad Sci USA (1989) <u>86</u>:1273-1277; Kirnbauer et al., <u>J Immunol</u> (1989) <u>142</u>:1922-1928).

It is known that damage to the human skin results in the expression of growth factors at the wound site (Clark and Henson (eds), The Molecular and Cellular Biology of Wound Repair (1988); Barbul et al. (eds), Progress in Clinical and Biological Research (1987) Vol. 266; Rappolee et al., Science (1988) 241:708-712; Antoniades et al., Proc Natl Acad Sci USA (1991) 88:565-569); and various approaches to the use of factors provided by cells in the healing of wounds have been tried.

First, several individual growth factors have been shown to modulate the wound healing process (Clark and Henson (eds), The Molecular and Cellular Biology of Wound Repair (1988); Pierce et al., J Cell Biol (1989)

35

109:429-440; Barbul et al. (eds), <u>Progress in Clinical</u> and <u>Biological Research</u> (1987), Vol. 266.

Second, it has also been attempted to use whole epithelial cells in wound healing. Application of allogenic keratinocyte grafts to surface wounds and 5 ulcerations in humans functions to promote the healing of these lesions has shown positive results (Phillips et al., Clin Res (1988) 36:684A; Burt et al., Br Med J (1989) 298: 915-917; Brian et al., Br Med J (1989) 298:917-919; Phillips and Gilchrest, Dermatol Surg Oncol 10 (1989) <u>15</u>:1169-1176; Phillips et al. <u>J Am Acad Dermatol</u> (1989) 21:191-199). However, the treatment of wounds with allogenic cells or individual growth factors includes inherent problems concerning safety and efficacy. The present invention endeavors to overcome 15 such problems.

Disclosure of the Invention

and use of a mixture of growth factors, both autocrine and paracrine, produced by human epithelial cells. This represents a desirable combination of factors capable of effecting wound healing and tissue repair. Such combinations of factors in their native proportion are particularly desirable for therapeutic purposes and can be so used by itself or in a pharmaceutical formulation. This mixture of growth factors is produced by harvesting conditioned medium from cultures of human epithelial cells grown in protein-free medium.

In one aspect, the invention relates to a method to produce human keratinocyte-derived conditioned medium factors (kdCMF), which method comprises culturing human epithelial cells in a protein-free medium to obtain a conditioned medium and recovering the conditioned medium from the culture.

10

15

20

25

30

Another aspect of the invention relates to the use of kdCMF to promote healing of surface wounds, ulcerations and other hypoproliferative skin pathologies in humans, and to pharmaceutical compositions useful for this purpose.

Still another aspect of the invention relates to the use of kdCMF as a supplement to cell culture medium for the purpose of promoting cell growth and viability of cells other than human keratinocytes.

An object of the invention is to provide a novel mixture of growth factors which growth factors include autocrine and paracrine growth factors which growth factors are present with respect to each other in substantially the same relative amounts in which they naturally occur indigenously within a mammal such as a human.

An advantage of the present invention is that the mixture of growth factors provides efficacious results when applied to a wound in terms of increasing the rate of wound healing.

A feature of the present invention is that the mixture of growth factors is non-toxic in that it includes naturally occurring growth factors in their naturally occurring proportional amounts.

These and other objects, advantages and features of the present invention will become apparent to those persons skilled in the art upon reading the details of the means of production and use as fully set forth below with reference being made to the accompanying examples forming a part hereof.

Detailed Description of the Invention

Before the present mixture of growth factors and methods of preparing and using such are described, it is to be understood that this invention is not limited to

30

35

the particular species (humans), cell types (human keratinocytes) or culture mediums described as such may, of course, vary. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only, and is not intended to be limiting since the scope of the present invention will be limited only by the appended claims.

It must be noted that as used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the 10 context clearly dictates otherwise. Thus, for example, reference to "a mixture" of growth factors may include a plurality of different, mixtures of growth factors obtained from different sources, reference to "an 15 autocrine" refers to one or more autocrine growth factor compounds alone or in combination with each other and reference to "the protein-standard medium" includes any such medium of the type described herein and of the type which would become apparent to those skilled in the art 20 upon reading this disclosure, and so forth.

The invention is directed to the use of "keratinocyte-conditioned medium factors" (kdCMF). As defined herein, kdCMF refers to the mixture of autocrine and paracrine factors which are produced by culturing human epithelial cells in a protein-free medium. Thus, when such epithelial cells are allowed to grow in a protein-free medium, the medium will contain a mixture of these factors produced by the cells. In its simplest form, the kdCMF of the invention is simply the conditioned medium harvested from such cultures.

The conditioned medium itself can also be further fractionated (using standard separation protocols based on charge, hydrophobicity, size or ligand affinity) into two or several fractions which retain mixtures of the secreted factors, although in altered ratio. Such

WO 93/04164 PCT/US91/06161

crude fractions can also be used in the wound-healing methods and cell proliferation methods of the invention and are another embodiment of kdCMF.

The conditioned medium can also be concentrated and/or freed of inorganic and small organic materials by dialysis and/or lyophilization and/or other methodologies. The resulting concentrated form of the conditioned medium also contains these factors, and is thus a more convenient form of kdCMF.

10

15

20

35

In its preferred form, the invention involves the purified mixture of growth factors which are obtained from the protein-free medium on which the epithelial cells are allowed to grow. The growth factors are purified but maintained so that the natural ratio of each of the growth factors to each other remains substantially undisturbed. It is believed that by maintaining the particular ratio of each growth factor to the other, it is possible to obtain a mixture of growth factors which is both safe and efficacious with respect to enhancing the rate of wound healing.

In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.

As used herein, the term "defined medium" refers to medium which contains no crude extracts or 25 common supplements such as pituitary extract, serum proteins, and so forth. "Defined medium" refers to the conventional understanding as it pertains to growth of cells in a medium containing no undefined additives, as that term is commonly used in the art. In the present 30 invention, however, "protein-free standard medium" also lacks exogenous artificial sources of specific growth factors such as EGF, $TGF\alpha$, or other polypeptides. illustrative embodiment of "protein-free standard medium" is described herein.

The term "complete medium" refers to high amino-acid (HAA) modified medium MCDB 153 (Pittelkow and Scott, Mayo Clin Proc (1986) 61:771-777, incorporated herein by reference to disclose such a medium) supplemented with 0.2% (v/v) bovine pituitary extract (BPE), culture grade EGF (10 ng/ml), insulin (5 μ g/ml), hydrocortisone (5 x 10⁻⁷ M), ethanolamine (1 x 10⁻⁴ M) and phosphoethanolamine (1 x 10⁻⁴ M), gentamicin sulfate

10 supplements.

15

20

25

30

35

One form of "defined medium" illustrated herein as "defined medium-1" refers to complete medium without BPE.

 $(\mu g/ml)$ or in KBM medium (Clonetics Corp.) with the same

"Protein-free standard medium" as illustrated herein as "protein-free standard medium-1" refers to complete medium without BPE, EGF and insulin.

The kdCMF can be produced using a variety of protocols which are similar to that described in Example 1 herein, and generally by plating human epithelial cells in complete, defined or protein-free standard medium at varying densities in different cell culture vessels or on different substrates. Alternative protocols utilize other complete, defined or protein-free media to plate the human keratinocytes. Once plated, the medium is changed to protein-free standard medium to facilitate the isolation of kdCMF. While human keratinocytes are preferred, related cell types (other human epithelial cells) which may or may not be immortalized are viable alternatives in the generation of kdCMF.

Although the preferred embodiment of the present invention involves the use of human epithelial cells and more specifically human keratinocytes, the present invention is intended to encompass other mixtures of growth factors which can be obtained from the culturing of non-human mammalian epithelial cells and

WO 93/04164 PCT/US91/06161

non-human mammalian keratinocytes. As will be apparent to those skilled in the art, certain modifications to the medium upon which those cells are grown should be made in order to allow for the efficient growth of such non-5 human cells. It may be most desirable to obtain certain non-human cells such as porcine epithelial cells or porcine keratinocytes in that the growth factors and growth factor mixtures produced by such cells might well be readily amenable for human use. Accordingly, the 10 present invention includes mixtures of human and nonhuman growth factors obtained from the culturing of human and non-human epithelial cells and specifically human and non-human keratinocytes, as well as pharmaceutical formulations containing such mixtures of growth factors 15 and methods of using such mixtures and formulations in order to promote wound healing.

Wound Healing

20

25

35

The human skin consists of a vascularized dermis that is separated by a basement membrane from the avascular epidermis. The epidermis is composed of several topologically organized compartments including a proliferative basal layer and post-mitotic suprabasal layers which differentiate and form the keratinized outer layer of the skin. It is generally regarded that proliferating keratinocytes within the basal layer of the epidermis must rely on the vascularized dermal layers for nutritive support.

.The wound-healing process is clearly a 30 complicated sequence of events which may involve neovascularization, synthesis of extracellular matrix components and stimulation of cell migration and proliferation. The exact identities and quantities of factors necessary for expedient healing of surface wounds in humans are not known, and all of the factors which

regulate the processes of wound-healing are not completely understood. Thus, the application of single growth factors (FGFs, EGF, TGFα, PDGFs, TGFβs) to promote the healing of wounds and ulcerations is of less benefit than the addition of preparations which contain factors that more closely mimic the array and concentration of factors produced by epidermal cells at the site of injury. Autonomously proliferating normal human keratinocyte cultures are analogous to wounded epidermis and therefore conditioned media from these cells will contain an array of wound healing/stimulating factors that will be of value in treating a variety of surface wounds, ulcerations and hypoproliferative pathologies in humans.

15 The application of kdCMF to surface wounds and epidermal pathologies in humans is an improvement over existing technologies. Unlike preparations containing a single purified growth factor, kdCMF is a complete mixture of keratinocyte-derived factors capable of 20 expediting the wound-healing process in a manner similar to that mediated by epidermal cells at the site of injury. kdCMF also offers advantages over the use of keratinocytes per se. Exposure to viral pathogens which may be present in the live cells derived from allogenic 25 donors is avoided as well, as is the exposure of patients to undefined antigenic contaminants (bovine serum, murine cell lines) associated with other methods currently used to culture human keratinocytes (Rheinwald and Green, Cell (1975) <u>6</u>:331-344). This avoids the possibility of 30 inducing serum sickness or other undesirable immunological reactions (Meyer et al., <u>H Trauma</u> (1988) 28:1054-1059; Johnson et al., <u>J Burn Care Rehabil</u> (1990) 11:504-509).

The conditions which may benefit from the application of kdCMF include, but are not limited to:

WO 93/04164 PCT/US91/06161

-10-

epidermal ulcerations (decubitus ulcers, ischemic ulcers, infarctive ulcers, vascular ulcers, and hemoreologic ulcers), surface wounds (thermal and chemical induced burns, abrasions, lacerations, incisions, skin graft donor sites, and skin graft recipient sites), lupus erythematosus, corticosteroid-induced atrophy, pemphigus, pemphigoid, androgenetic alopecia and alopecia areata.

For application of the kdCMF of the invention therapeutically, the active ingredient is formulated into suitable topical compositions, including salves, creams, lotions, solutions, and the like. Additional excipients and palliative factors may also be added. Formulations suitable for topical compositions are well known in the art and may be found, for example, in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Company, Easton, PA.

The compositions useful in wound healing may also include autologous cells (normal human keratinocytes and/or fibroblasts) or other purified growth factors ($TGF\alpha$, $TGF\beta$, FGFs, HB-EGF, EGF, AR, PDGFs, epithelins). Simultaneous or additional administration of these cells and/or factors will be of benefit in mediating the woundhealing process. Moreover, application of kdCMF with or without the above-described additives with bandages, or with solid matrices or supports (collagen, collagenglycosaminoglycan) will be of value as effective methods of delivering kdCMF to lesions and wounds.

In addition to therapeutic use, the kdCMF of the invention may be used as a supplement in culturing various cells which can benefit from this array of growth factors. Suitable cell types which can be benefited in this way include various epithelial cultures, such as those derived from the skin trachea, bronchia, urogenital tract and mammary epithelium.

î,

35

5

10

15

20

25

WO 93/04164 PCT/US91/06161

-11-

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make the growth factor mixtures of the invention and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, time, etc.), but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in degrees centigrade and pressure is at or near atmospheric.

Preparation A

15 <u>Preparation of Human Keratinocyte Cultures</u>

Primary cultures of human keratinocytes can be isolated by the trypsin float technique as described in Wille et al., <u>J Cell Physiol</u> (1984) <u>121</u>:31-34, or other suitable methods. Stock cultures can be maintained (Shipley et al., <u>J Cell Physiol</u> (1989) <u>138</u>:511-518; Shipley and Pittelkow, <u>Arch Dermatol</u> (1987) <u>123</u>:1541a-1544a) in an actively growing state in a complete or defined medium.

25

30

20

10

Example 1

Preparation of kdCMF

Keratinocytes are plated in complete or defined medium at a density of 1-5 x 10³ cells/cm² in tissue culture dishes or other suitable vessels. After 1-3 days of incubation, the cells are washed 3 times with Hepes buffered normal saline and the medium replaced with protein-free standard medium. After 24 hours of additional incubation, the medium is discarded and replaced with fresh protein-free standard medium.

Protein-free standard medium conditioned by human keratinocytes is collected every 24-48 hours for 4-5 days until the cells reach 90-95% confluency. Keratinocyte conditioned medium (CM) is collected and frozen at -80°C. CM can be later thawed, pooled and concentrated. In addition to the original components of protein-free standard medium, concentrated keratinocytederived CM contains kdCMF.

The bioactivity of kdCMF is assayed on any cell type which responds to the factors present in kdCMF.

AKR-2B, NR6, human dermal fibroblasts, Balb/MK, and human keratinocytes at clonal density are used to detect kdCMF bioactivity (Cook et al., <u>J Cell Physiol</u> (1991) 146:277-289).

15 The instant invention is shown and described herein in what is considered to be the most practical and preferred embodiments with respect to the growth factor mixtures, their methods of preparation, formulation and use. It is recognized, however, that departures may be made therefrom which are within the scope of the invention and that modifications will occur to one skilled in the art upon reading this disclosure.

25

30

-13-

Claims

- 1. A method of preparing mammalian keratinocyte-derived conditioned medium factors (kdCMF) comprising:
- a) culturing mammalian epithelial cells in a protein-free standard medium to obtain a conditioned medium containing said factors; and
- b) recovering the conditioned medium from the 10 culture.
 - 2. The method of claim 1, wherein the epithelial cells are keratinocytes.
- 15 3. The method as claimed in claim 1, wherein the epithelial cells are human epithelial cells.
 - 4. The method as claimed in claim 3, wherein the epithelial cells are human keratinocytes.

 - 6. The method of claim 1, further comprising concentrating the kdCMF from said conditioned medium using dialysis.
 - 7. The method of claim 5, further comprising lyophilizing the kdCMF.

35

30

20

- 8. A method to promote the healing of surface wounds in humans which comprises applying the kdCMF of claim 1 to the surface wound.
- 9. The method of claim 8, wherein the surface wound is a thermal or chemical induced burn, an abrasion, laceration or incision, or a skin graft donor or recipient site.
- 10. The method of claim 8, wherein the kdCMF is applied in the form of a solution, salve, lotion, or creme.
- 11. A method to promote the healing of surface
 15 ulcerations or hypoproliferative skin pathologies in
 humans which comprises applying the kdCMF of claim 1 to
 the surface ulcerations or hypoproliferative skin
 pathologies.
- 20 12. The method of claim 11, wherein the surface ulceration is a decubitus, ischemic, infarctive, vascular or hemoreologic ulcer.
- 13. The method of claim 11, wherein the 25 hypoproliferative skin pathology is lupus erythematosus, corticosteroid-induced atrophy, pemphigus, pemphigoid, androgenic alopecia or alopecia areata.
- 14. The method of claim 11, wherein the kdCMF 30 is applied in the form of a solution, salve, lotion, or creme.
- 15. A method to promote cell growth and viability of responsive mammalian cells in culture which comprises providing to said culture the kdCMF of claim 1.

16. A pharmaceutical composition which comprises the kdCMF of claim 1 in admixture with at least one pharmaceutical excipient.

5

- 17. The composition of claim 16, which further comprises growth factors.
- 18. The composition of claim 16, which further comprises normal human keratinocytes or fibroblasts.
 - 19. A medical article which comprises a solid substrate that includes the kdCMF of claim 1.
- 15 20. The article of claim 19, wherein said substrate is a bandage.
- 21. The article of claim 17, wherein said substrate is a collagen or collagen-GAG-containing 20 matrix.
 - 22. The article of claim 17, wherein said substrate is an artificial biocompatible matrix.

25

30

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/06161

According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): C12N 57/00 U.S.Cl. 435/240.2 IF FELDS SEARCHED Minimum Decomentation Searched? Classification Symbols U.S.Cl. 435/240.1; 240.2 Documentation Searched other than Minimum Documentation to the Estimate such Documents are included in the Falls' Searched 4 Biosis "Pratein Free Medin", AU= "Shipley G or Shipley G D", "Growth factor", "Conditioned" til. DOCUMENTS CONSIDERED TO BE RELEVANT! Causort* Classification Symbols Y Cancer Research, Volume 49, issued 31/399, Total Cancer Research			ICATIO	N OF SUBJECT MATTER (il several classificati	ion symbols apply, indicate all) *	
IFFELDS SEARCHED Minimum Documentation Searched? Classification System U.S.Cl. 435/240.1; 240.2 Documentation Searched other than Minimum Documentation to the Estent that such Documental are included in the Fields Searched 4 Biosis "Pratein Free Medin", AU= "Shipley G or Shipley G D", "Growth factor", "Conditioned" III. DOCUMENTS CONSIDERED TO BE RELEVANT: Catagory: Citation of Document, II with indication, where endrogenie, of the relevant casaspee II Relevant to Claim No. II Y Cancer Research, Volume 49, issued, 159, D. Boyd et al., "Exemination of the Effects of D. Boyd et al., "Exemination of the Effects of D. Boyd et al., "Exemination of the Production of Urokinase and the Expression of the Planmanogen Activator Receptor in a Human Colon Cancer Cell Line," pages 2427-2432, see entire document. Journal of Cellular Physiology, Volume 149, issued 1989, Pittelkow et al., "Sexue-Free Culture of Normal Human Relanocytem: Growth Kinetics and Growth Factor Requirements," pages 555-76, see entire document. Journal of Cellular Physiology, Volume 128, issued 1989, G.D. Shipley, et al., "Growth of Insulate and Growth Factor Requirements," ages 555-76, see entire document to be plantaged by Acidic and Besic Fibroblast Growth Factor," pages 511-518, see entire document of the Strong	1. C	LASSIF	internati	onal Patent Classification (IPC) or to both National	Classification and IPC	٠
Tissefication System U.S.C1. 435/240.1; 240.2 Decumentation Searched other than Minimum Documentation to the Citient has such Documents are included in the Fields Searched 4 Biosis "Pratein Free Medin", AU= "Shipley G or Shipley G D", "Growth factor", "Conditioned" iii. DOCUMENTS CONSIDERED TO BE RELEVANT* Citieory* Citient of Document, "with indication, where approximate, of the relevant passages "Relevant to Claim No. "I Y Cancer Research, Volume 49, issued 1599, D. Boyd et al., "Examination of the Effects of Epiderment Growth Factor on the Production of Urokkinase and the Expression of the Plasmingen Activator Receptor in a Human Colon Cancer Cell Line," pages 2427-2432, see entire document. Journal of Cellular Physiology, Volume 140, issued 1989, Pttekkov et al., "Serua-Free Culture of Normal Human Relanocytes: Growth Kinetics and Growth Factor Requirements," pages 353-76, see entire document. Journal of Cellular Physiology, Volume 138, entire document. Journal of Collular Physiology, Volume 138, entire document. Publication of Collular Physiology, Volume 138, entire document. Journal Human Keratinocytes and Fibrobacks in Serua-Free Nedum In Stitulates by Actidic and Beats Fibroblast Growth Factor, "pages 511-516, see entire document by Dublande on or situ the international college of theory underlying to which is case to establish the publication deal of another college of the production of the production of the college of the production but itself than the production of the pr	֓֞֞֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓	IPC(5)	: C12	N 5/00		
Classification System Classification Symbols U.S.C1. 435/240.1; 240.2 Documentation Searched other than Minimum Documentation to the Estent that such Documents are included in the Fields Searched* Biosis "Pratein Free Medin", AU= "Shipley G or Shipley G D", "Growth factor", "Conditioned" III. DOCUMENTS CONSIDERED TO BE RELEVANT* Cissor* Citation of Document, "with indication, where appropriate, of the relevant dasasses "P Cancer Research, Volume 49, issued 1509, D. Boyd et al., "Examination of the Effocts of Directions and the Expression of the Plasminogen Activator Receptor in a Numan Colon General Call Line," pages 2427-2429, see entire document. Journal of Callular Physiology, Volume 149, issued 1989, Pittelkov et al., "Serus-Free Culture of Normal Human Melanocytes: Growth Kinatics and Orovih Factor Requirements," pages 565-576, see entire document. Journal of Callular Physiology, Volume 138, issued 1989, G.D. Shipley, et al., "Growth of Normal Human Keratinocytes and Fibroblacts in Serum-Free Medium Is Stimulated by Actics and Serum-Free Medium Is Stimulated by Actics and Serum-Free Medium Is Stimulated by Actics and Basic Fibroblast Growth Factor," pages 511-518, gee entire document. "A document defining the general state of the all which is not call the Serum of Basic Fibroblast Growth Factor," pages 511-518, gee entire document. "A document defining the general state of the stimulated by Actics and Serum-Free Medium Is Stimulated by Actics and Fibroblast in Serum-Free Nedium Is Stimulated by Actics and Fibroblast in Serum-Free Nedium Is Stimulated by Actics and Serum-Free Nedium Is Stimulated by Actics and Fibroblast in Serum-Free Nedium Is Stimulated by Actics and Serum-Free Nedium Is Stimulated by Actics and Fibroblast in Serum-Free Nedium Is Stimulated by Actics and Serum-Free Nedium Is Serum-Free Nedium	τ	J.S.CL	J.: 43	5/240.2		
U.S.C1. 435/240.1; 240.2 Decumentation Searched other than Minimum Documentation to the Estent has such Documenta are included in the Fields Searched. Biosis "Practein Free Medin", AU= "Shipley G or Shipley G D", "Growth factor", "Conditioned" III. DOCUMENTS CONSIDERED TO BE RELEVANT: Category* Classion of Document, II with indication, where appropriate, of the relevant passages II Relevant to Claim No. II Y Cancer Research, Volume 49, issued 1999, 1-7 Category* Chairman Growth Fector on the Production of Epidermal Growth Fector on the Production of Urokinsoe and the Expression of the Production of Epidermal Growth Fector on the Production of Cell Line,* pages 427-2427, see entire document. Journal of Cellular Physiology, Volume 149, issued 1999, Pittelkov et al., "Growth Free Culture of Rormal Human Helanocytes" Forum Free Culture of Rormal Human Helanocytes: Growth Kinetics and Growth Factor Requirements,* pages 353-376, see entire document. Journal of Cellular Physiology, Volume 138, Serum-Free Medium Is Stituolated by Acidic end Serum-Free Medium Is Stituolated by Acidic end Serum-Free Medium Is Stituolated by Acidic end Beaic Fibroblast Growth Factor, pages 511-518, see entire document that the major the service of the massage of the production of Common which may throw doubts on priority clamba; or which is considered movel or cannot be an extent cannot be considered movel or can	-	FIELDS :	SEARCH	IED	····	
U.S.C1. 435/240.1; 240.2 Decumentation Searched other than Minimum Documentation to the Estent that such Documents are included in the Fields Searched. Biosis "Pratein Free Medin", AU= "Shipley G or Shipley G D", "Growth factor", "Conditioned" Iti. DOCUMENTS CONSIDERED TO BE RELEVANT: Category. Chainon of Document, 11 with indication, where appropriate, of the relevant passages 12 Relevant to Claim No. 12 Y Cancer Research, Volume 49, issued to the Effects of D. Boyd et al., "Examination of the Effects of Urokinase and the Expression of the Plasmingen Activator Receptor in a Human Colon Gener Cell Line," pages 2427-2432, see entire document. Y Journal of Cellular Physiology, Volume 130, issued 1989, Plateklov et al., "Serum-Free Culture of Normal Human Relanocytes: Growth Kinetice and Growth Factor Requirements," pages 555-376, see entire document. Journal of Cellular Physiology, Volume 138, issued 1989, G.D. Shipley, et al., "Growth of Normal Human Keratinocytes and Fibroblasts in Serum-Free Medium In Stitulated by Acidic and Beasic Fibroblast Growth Factor," pages 511-316, see entire document. **Specul categories of cited documents: " **Specul categories of						
Documentation Searched other than Minimum Documentation to the Estent that such Documents are included in the Fields Searched * Biosis "Pratein Free Medin", AU= "Shipley G or Shipley G D", "Growth factor", "Conditioned" III. DOCUMENTS CONSIDERED TO SE RELEVANT * Category * Clastion of Document, 11 with indication, where sporophate, of the relevant passages 12 Y Cancer Research, Volume 49, issued, 1999, D. Boyd et al., "Examination of the Effects of D. Boyd et al., "Examination of the Effects of Urokinage and the Expression of the Production of Epiddermal Growth Factor on the Production of Cell Line, "pages 2427-2432, see entire document. Journal of Cellular Physiology, Volume 148, issued 1989, Pittelkov et al., "Serus-Free Culture of Normal Human Melanocytes: Growth Kinetics and Growth Factor Requirements," pages 355-376, see entire document. Journal of Cellular Physiology, Volume 138, issued 1989, G.D. Shipley, et al., "Growth of Normal Human Melanocytes: Growth Factor Requirements," pages 355-376, see entire document. Y Journal of Cellular Physiology, Volume 138, issued 1989, G.D. Shipley, et al., "Growth of Normal Human Melanocytes and Fibroblasts in Serus-Free Hedium Is Stimulated by Acidic and Besic Fibroblast Growth Factor," pages 511-518, see entire document. **A document defining the general state of the sit which is not considered to be of particular relevance and Fibroblast in the solution and other section but international filing date of the strain of particular relevance in the claimed invention of the strain by principle of canaders of the strain by principle of canaders of considered to excellation at other section relevance in the claimed invention of the strain by principle of canaders of the strain by principle of can	Clas	silication	System	Clas	safication Symbols	
Documentation Searched other than Minimum Documentation to the Estent that such Documents are included in the Fields Searched * Biosis "Pratein Free Medin", AU= "Shipley G or Shipley G D", "Growth factor", "Conditioned" III. DOCUMENTS CONSIDERED TO SE RELEVANT * Category * Clastion of Document, 11 with indication, where sporophate, of the relevant passages 12 Y Cancer Research, Volume 49, issued, 1999, D. Boyd et al., "Examination of the Effects of D. Boyd et al., "Examination of the Effects of Urokinage and the Expression of the Production of Epiddermal Growth Factor on the Production of Cell Line, "pages 2427-2432, see entire document. Journal of Cellular Physiology, Volume 148, issued 1989, Pittelkov et al., "Serus-Free Culture of Normal Human Melanocytes: Growth Kinetics and Growth Factor Requirements," pages 355-376, see entire document. Journal of Cellular Physiology, Volume 138, issued 1989, G.D. Shipley, et al., "Growth of Normal Human Melanocytes: Growth Factor Requirements," pages 355-376, see entire document. Y Journal of Cellular Physiology, Volume 138, issued 1989, G.D. Shipley, et al., "Growth of Normal Human Melanocytes and Fibroblasts in Serus-Free Hedium Is Stimulated by Acidic and Besic Fibroblast Growth Factor," pages 511-518, see entire document. **A document defining the general state of the sit which is not considered to be of particular relevance and Fibroblast in the solution and other section but international filing date of the strain of particular relevance in the claimed invention of the strain by principle of canaders of the strain by principle of canaders of considered to excellation at other section relevance in the claimed invention of the strain by principle of canaders of the strain by principle of can						
Documentation Searched other than Minimum Documentation to the Estent that such Documents are included in the Fields Searched * Biosis "Pratein Free Medin", AU= "Shipley G or Shipley G D", "Growth factor", "Conditioned" III. DOCUMENTS CONSIDERED TO SE RELEVANT * Category * Clastion of Document, 11 with indication, where sporophate, of the relevant passages 12 Y Cancer Research, Volume 49, issued, 1999, D. Boyd et al., "Examination of the Effects of D. Boyd et al., "Examination of the Effects of Urokinage and the Expression of the Production of Epiddermal Growth Factor on the Production of Cell Line, "pages 2427-2432, see entire document. Journal of Cellular Physiology, Volume 148, issued 1989, Pittelkov et al., "Serus-Free Culture of Normal Human Melanocytes: Growth Kinetics and Growth Factor Requirements," pages 355-376, see entire document. Journal of Cellular Physiology, Volume 138, issued 1989, G.D. Shipley, et al., "Growth of Normal Human Melanocytes: Growth Factor Requirements," pages 355-376, see entire document. Y Journal of Cellular Physiology, Volume 138, issued 1989, G.D. Shipley, et al., "Growth of Normal Human Melanocytes and Fibroblasts in Serus-Free Hedium Is Stimulated by Acidic and Besic Fibroblast Growth Factor," pages 511-518, see entire document. **A document defining the general state of the sit which is not considered to be of particular relevance and Fibroblast in the solution and other section but international filing date of the strain of particular relevance in the claimed invention of the strain by principle of canaders of the strain by principle of canaders of considered to excellation at other section relevance in the claimed invention of the strain by principle of canaders of the strain by principle of can	١,	וו כ רו	1	/35/240 1 240 2	•	
Biosis "Pratein Free Medin", AU= "Shipley G or Shipley G D", "Growth factor", "Conditioned" til. DOCUMENTS CONSIDERED TO SE RELEVANT * Category* Citation of Document, "with indication, where appropriate, of the relevant passages 12 Relevant to Claim No. 12 Y Cancer Research, Volume 49, issued, 1599, D. Boyd et al., "Examination of the Effects of Epidermal Growth Factor on the Production of Epidermal Growth Factor on the Production of Urokinase and the Expression of the Plasminagen Activator Receptor in a Numan Colon Cancer Cell Line," pages 2427-2432, see entire document. Y issued 1989, Pittelkov et al., "Serus-Free Culture of Normal Human Melanocytes: Growth Kinetics and Growth Factor Requirements," pages 555-576, see entire document. Y issued 1989, D.D. Shipley, et al., "Growth of issued 1989, D.D. Shipley, et al., "Growth of Normal Human Kerathnocytes and Fibroblasts in Serus-Free Nedium Is Stimulated by Acidic and Basic Fibroblast Growth Factor," pages 511-518, see entire document. **Special categories of cited documents: 10 **Comment defining the general state of the art which is not consecred to be of Danicular relevance **Comment of particular relevance **Comment of particular relevance **Comment of particular relevance is a concient of consecred to be of Danicular relevance **Comment of particular relevance: the claimed invention of consecred to be of Danicular relevance and particular relevance; the claimed invention of consecred to be of Danicular relevance and particular relevance; the claimed invention of consecred to be of Danicular relevance and particular relevance; the claimed invention of consecred to be of Danicular relevance; the claimed invention of consecred to be of Danicular relevance; the claimed invention of consecred to be of Danicular relevance; the claimed invention of consecred to be of Danicular relevance; the claimed invention of consecred to involve an inventi	\ \	0.5.01	••			
Biosis "Pratein Free Medin", AU= "Shipley G or Shipley G D", "Growth factor", "Conditioned" iii. DOCUMENTS CONSIDERED TO BE RELEVANT 5 Category* Chains of Document, " with indication, where appropriate, of the relevant passages " Y Cancer Research, Volume 49, issued, 1999, D. Boyd et al., "Examination of the Effects of D. Boyd et al., "Examination of the Effects of Urokinase and the Expression of the Plasminagen Activator Receptor in a Human Colon Cancer Cell Line, "pages 2427-2432, see entire document. Y Journal of Cellular Physiology, Volume 149, I issued 1989, Pittelkov et al., "Serus-Free Culture of Kormal Human Melanocytes: Growth Kinetics and Growth Factor Requirements," pages 565-376, see entire document. Journal of Cellular Physiology, Volume 138, I issued 1989, G.D. Shipley, et al., "Growth of I issued 1989, G.D. Shipley, et al., "Growth of Serus-Free Medium Is Stimulated by Acidic and Basic Fibroblast Growth Factor," pages 511-518, see entire document. **Special categories of Cited documents: 10 "A" document defining the general state of the art which is not considered to be of particular relevance of international filing date or priority gate and not in conflict with the application but on the considered of the order of the priority claiming of the conflict with the application but on the considered of the conflict with the application but on the considered of the conflict with the application but on the considered of the conflict with the application but on the considered of the conflict with the application but on the considered of the conflict with the application but on the considered of the conflict with the application but on the considered of the conflict with the application but on the considered of the conflict with the application but on the considered of the conflict with the application but on the considered of the conflict with the application but on the considered of the conflict with the application but on the considered of the conflict with the application but on the considered	-			Documentation Searched other than	Minimum Documentation	
"" "Growth factor", "Conditioned" III. DOCUMENTS CONSIDERED TO BE RELEVANT* Citation of Document, " with indication, where appropriate, of the relevant passages " Relevant to Claim No. 9 Y Cancer Research, Volume 49, issued 1999, D. Boyd et al., "Examination of the Effects of Epidermal Growth Factor on the Production of Urokinase and the Expression of the Plasminogen Activator Receptor in a Human Colon Cancer Cell Line, "pages 2427-2432, see entire document. Journal of Cellular Physiology, Volume 149, issued 1989, Pittelkov et al., "Serum-Free Culture of Normal Human Melanocytes: Growth Kinetics and Growth Factor Requirements," pages 555-576, see entire document. Journal of Cellular Physiology, Volume 138, serum-Free Redum Is Stimulated by Actidic and Serum-Free Redum Is Stimulated in Serum Is Stimulated Serum Is Serum Is Stimulated Serum Is Serum Is Stimulated Serum Is Seru				to the Extent that such Documents are	included in the Field Control	
iii. DOCUMENTS CONSIDERED TO BE RELEVANT* Category* Citation of Document, "I with indication, where appropriate, of the relevant passages 12 Relevant to Claim No. "1 Y Cancer Research, Volume 49, issued, 159, D. Boyd et al., "Examination of the Effects of D. Boyd et al., "Examination of the Effects of Urrekinase and the Expression of the Production of Urrekinase and the Expression of the Plasminogen Activator Receptor in a Numen Colon Cancer Cell Line, "pages 2427-2432, see entire document. Journal of Cellular Physiology, Volume 140, "Sarua-Free Culture of Roymal Human Helanocytes: Growth Kinetics and Growth Factor Requirements," spages 555-576, see entire document. Journal of Cellular Physiology, Volume 138, seued 1989, G.D. Shipley, et al., "Growth of Issued 1989, G.D. Shipley, et al., "Growth of Normal Human Keratinocytes and Fibroblasts in Scrum-Free Medium 18 Stimulated by Acidic and Basic Fibroblast Growth Factor," pages 511-518, see entire document. * Spacial categories of cited documents: "0" * Spac	;	Biosis "Growt	"Pra	tein Free Medin", AU= "Shiptor", "Conditioned"	pley G or Shipley G D	',
Y Cancer Research, Volume 49, issuedAilS9, D. Boyd et al., "Examination of the Effecte of Epidermal Growth Factor on the Production of Urokinase and the Expression of the Plasminogen Activator Receptor in a Numan Colon Cancer Cell Line, "pages 2427-2432, see entire document. Journal of Cellular Physiology, Volume 148, issued 1989, Pittelkow et al., "Serum-Free Culture of Rormal Human Melanocytes: Growth Kinetics and Growth Factor Requirements," pages 565-576, see entire document. Journal of Cellular Physiology, Volume 138, issued 1989, B.D. Shipley, et al., "Growth of Normal Human Keratinocytes and Fibroblasts in Serum-Free Redum is Stimulated by Actics and Basic Fibroblast Growth Factor," pages 511-518, see entire document. **Special categories of cited documents: "	1					
Y Cancer Research, Volume 49, issued, 1589, D. Boyd et al., "Exemination of the Effects of Epidermal Growth Factor on the Production of Epidermal Growth Factor on the Production of Urokinase and the Expression of the Plasminogen Activator Receptor in a Numan Colon Cancer Cell Line, "pages 2427-2432, see entire document. Journal of Cellular Physiology, Volume 148, issued 1989, Pittelkow et al., "Serum-Free Culture of Normal Human Helanocytes: Growth Kinetics and Growth Factor Requirements," pages 555-576, see entire document. Journal of Cellular Physiology, Volume 138, issued 1989, G.D. Shipley, et al., "Growth of issued 1989, G.D. Shipley, et al., "Growth of Serum-Free Medium Is Stimulated by Actic and Basic Fibroblast Growth Factor," pages 511-518, see entire document "Y seeler document but published on or after the international fing date "" service document but published on or after the international fing date "" document which may throw doubts an granty clamics or which is cred to establish them the specified of comment performed to be accomment of the same disease to comment a consider releaser; the claimed invention cannot be considered to evide an invention cannot be considered in one or more other such occument is combined with one or more other such occument is combined with one or more other such occument is accomment as combined with one or more other such occument is accomment on the considered in order of the same patent lamily IV. CERTIFICATION	 		MENTS	CONSIDERED TO BE RELEVANT	riale, of the relevant passages 12	Relevant to Claim No. 13
Epidermal Growth Factor on the Production of Urokinase and the Expression of the Plasminogen Activator Receptor in a Human Colon Cancer Cell Line, pages 2427-2432, see entire document. Journal of Cellular Physiology, Volume 148, issued 1989, Pittelkov et al., "Serum-Free Culture of Normal Human Helanocytes: Growth Kinetics and Growth Factor Requirements," pages 565-376, see entire document. Journal of Cellular Physiology, Volume 138, entire document. Journal of Cellular Physiology, Volume 138, See entire document. Journal of Cellular Physiology, Volume 138, See entire document. Journal of Cellular Physiology, Volume 138, Serum-Free Redium Is Stimulated by Actidic and Serum-Free Redium Is Stimulated by Actidic and Basic Fibroblast Growth Factor, pages 511-518, see entire document "The document defining the general state of the art which is not considered to be of particular relevance "The activation of other application but cannot be considered novel or cannot be considered no	Cat	edotA .	Citi	lion of Document, White the		
Epidermal Growth Factor on the Production of Epidermal Growth Factor on the Production of Urokinase and the Expression of the Plasminogen Activator Receptor in a Human Colon Cancer Cell Line, "pages 2427-2432, see entire document. Journal of Cellular Physiology, Volume 148, issued 1989, Pittelkov et al., "Serua-Free Culture of Normal Human Melanocytes: Growth Kinetics and Growth Factor Requirements," pages 565-376, see entire document. Journal of Cellular Physiology, Volume 138, issued 1989, G.D. Shipley, et al., "Growth of Normal Human Keratinocytes and Fibroblasts in Serua-Free Medium Is Stimulated by Actidic and Basic Fibroblast Growth Factor," pages 511-518, see entire document but published on or siter the international filing cate "I document which may throw doubts on priority claims) or which is crited to establish the publication or other special research (see) "I document published prior to the international filing date but in the priority of the second respond to special research in expression to special search or other means "P document published prior to the international filing date but is than the priority date claimed IV. CERTIFICATION Journal of Cellular Physiology, Volume 148, Serua-Free Culture 10-7. Serua-Free Culture 10-8. Serua-Free Culture 10-8. Serua-Free Culture 10-8. Serua-Free Culture 10-7. Serua-Free Culture 10-		- 1	•			
Epidermal Growth Factor on the Production of Epidermal Growth Factor on the Production of Urokinase and the Expression of the Plasminogen Activator Receptor in a Human Colon Cancer Cell Line, "pages 2427-2432, see entire document. Journal of Cellular Physiology, Volume 148, issued 1989, Pittelkov et al., "Serua-Free Culture of Rormal Ruman Helanocytes: Growth Kinetics and Growth Factor Requirements," pages 565-376, see entire document. Journal of Cellular Physiology, Volume 138, entire document. Journal of Cellular Physiology, Volume 138, Normal Ruman Keratinocytes and Fibroblasts in Serua-Free Redium Is Stimulated by Actidic and Serua-Free Redium Is Stimulated by Actidic and Basic Fibroblast Growth Factor," pages 511-518, see entire document "Take document oublished after the international filing date or priority date and not in conflict with the application but considered novel or theory underlying the invention of the section reson (as specifies) "To document which may throw doubts on priority claim(s) or which is cried to establish the publication date of another citation or other special reson (as specifies) "Co document published prior to the international filing date but the reporty date claimed IV. CERTIFICATION To destination of the plant of the same patent lamily To document published prior to the international filing date but the priority date claimed IV. CERTIFICATION	1	- 1			Ól Mau	
Epidermal Growth Factor on the Production of Epidermal Growth Factor on the Production of Urokinase and the Expression of the Plasminogen Activator Receptor in a Human Colon Cancer Cell Line, "pages 2427-2432, see entire document. Journal of Cellular Physiology, Volume 148, issued 1989, Pittelkov et al., "Serua-Free Culture of Rormal Ruman Helanocytes: Growth Kinetics and Growth Factor Requirements," pages 565-376, see entire document. Journal of Cellular Physiology, Volume 138, entire document. Journal of Cellular Physiology, Volume 138, Normal Ruman Keratinocytes and Fibroblasts in Serua-Free Redium Is Stimulated by Actidic and Serua-Free Redium Is Stimulated by Actidic and Basic Fibroblast Growth Factor," pages 511-518, see entire document "Take document oublished after the international filing date or priority date and not in conflict with the application but considered novel or theory underlying the invention of the section reson (as specifies) "To document which may throw doubts on priority claim(s) or which is cried to establish the publication date of another citation or other special reson (as specifies) "Co document published prior to the international filing date but the reporty date claimed IV. CERTIFICATION To destination of the plant of the same patent lamily To document published prior to the international filing date but the priority date claimed IV. CERTIFICATION		Y	c.	ncer Research, Volume 49, 188	neg v 1888.	1-7
Epidermal Growth Factor of the Plasminogen Urokinase and the Expression of the Plasminogen Activator Receptor in a Human Colon Cancer Cell Line, "pages 2427-2432, see entire document. Journal of Cellular Physiology, Volume 148, of Normal Human Helanocytes: Growth Kinetics and Growth Factor Requirements, "pages 355-376, see entire document. Journal of Cellular Physiology, Volume 138, of Normal Human Keratinocytes and Fabroblasts in Normal Human Keratinocytes and Fabroblasts in Serum-Free Medium Is Stimulated by Acidic and Basic Fibroblast Growth Factor, "pages 311-518, see entire document but published on or sites the international filing date "-" document but published on or sites the international filing cate "-" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of approximation or other special reson its specifies) "O' document published prior to the international filing date but its rhan the priority date claimed IV. CERTIFICATION To document published prior to the international filing date but its rhan the priority date claimed IV. CERTIFICATION		•	p.	Boyd et al., "Examination of	the Ellects of	1
Activator Receptor in Receptor Line, * pages 2427-2432, see entire document. Cell Line, * pages 2427-2432, see entire document. Journal of Cellular Physiology, Volume 140, issued 1989, Pittelkov et al., *Serus-Free Culture of Normal Human Melanocytes: Growth Kinetics and Growth Factor Requirements, * pages 565-576, see entire document. Journal of Cellular Physiology, Volume 138, issued 1989, G.D. Shipley, et al., *Growth of Normal Human Keratinocytes and Fibroblasts in Serum-Free Medium Is Stimulated by Acidic and Basic Fibroblast Growth Factor, * pages 511-518, see entire document. **Special categories of cited documents: **10 **A* document defining the general state of the art which is not considered to be of paincular relevance filing date **Comment defining the pages attention and filing date filing date **Comment which may throw doubts on priority claimfa) or which is cited to establish the publication date of another citation or other sectial reason tas specified) **Comment referring to an oral disclosure, use; exhibition or other means. **P** document published prior to the international filing date but later than the priority date claimed **Vocational Comment in Conflict with the application but invention considered to oral considered document of particular relevance: the claimed invention cannot be considered document involves an inventive step when the document involves an		- 1	E	pidermal Growth Factor on the	the Plasminogen	[
Journal of Cellular Physiology, Volume 140, issued 1989, Pittelkov et al., "Serus-Free Culture of Normal Human Helanocytes: Growth Kinetics and Growth Factor Requirements," pages 565-576, see entire document. Journal of Cellular Physiology, Volume 138, issued 1989, G.D. Shipley, et al., "Growth of Normal Human Keratinocytes and Fibroblasts in Serum-Free Medium Is Stimulated by Acidic and Basic Fibroblast Growth Factor, " pages 511-518, see entire document. *Special categories of cited documents: 10 "A" document defining the general state of the art which is not considered to be of particular relevance: the claimed invention of their means. "E" serier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication due to the research season (as spacefied) "O" document referring to an oral disclosure, use, skiblition or other means. "P" document published prior to the international filing date but late than the priority date claimed IV. CERTIFICATION 1-7. 1-7	1	- 1	Uı	rokinase and the Expression of	colon Cancer	
Journal of Cellular Physiology, Volume 140, issued 1989, Pittelkov et al., "Serus-Free Culture of Normal Human Melanocytes: Growth Kinetics and Growth Factor Requirements," pages 565-576, see entire document. Journal of Cellular Physiology, Volume 138, issued 1989, G.D. Shipley, et al., "Growth of Normal Human Keratinocytes and Fibroblasts in Serus-Free Medium Is Stimulated by Acidic and Serus-Free Medium Is Stimulated by Acidic and Basic Fibroblast Growth Factor, "pages 511-518, see entire document. "T" later document outlished siter the international filing date or priority date and not in conflict with ine application but cited to understand the principle of theory underlying the invention "T" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step "Y" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance: the claimed invention cannot be considered novel or c	-	3	Ĉ	11 Line, * pages 2427-2432, me	e entire document.	
* Special categories of cited documents: 10 * Special categories of cited documents: 10 * Special categories of cited documents: 10 * A document defining the general state of the art which is cited to establish the published on or after the international miching categories of cited document published and not in conflict with the application but cannot be considered to early deciment which is cited to early and the published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle of theory underlying the invention which is cited to establish the published on or after the international cannot be considered novel or cannot be considered to involve an inventive step when the document published goes to the priority date and not in conflict with the application but cited to understand the principle of theory underlying the invention of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document published goes to be part of the international filing date but later than the priority date claimed 10. **T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle of theory underlying the cited to exclude the priority date claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such as the date of particular relevance: the claimed invention cannot be considered to involve an inventive and priority date claimed invention or other macros. **Control of particular relevance: the claimed invention cannot be considered to involve an inventive and priority date claimed. **Control of particular relevance: the claimed invention cannot be considered to involve an inventive and priority date claimed. **Control of particular relevance: the claimed invention cannot be considere						1
of Normal Human Relandoytes of Growth Factor Requirements, pages 565-376, see entire document. Journal of Cellular Physiology, Volume 138, 1884 1989, G.D. Shipley, et al., "Growth of Serum-Free Redium Is Stimulated by Acidic and Basic Fibroblast Growth Factor, pages 511-518, gee entire document. *Special categories of cited documents: 9	1	v		ACCO DARRENT DOWNER BL.	-281.0m-1.46	1-7
The state of the s		x ,				
Journal of Cellular Physiology, Volume 138, issued 1989, G.D. Shipley, et al., "Growth of Normal Human Keratinocytes and Fibroblasts in Serum-Free Medium Is Stimulated by Acidic and Basic Fibroblast Growth Factor, "pages 511-518, see entire document. *The later document published siter the international filing date and not in conflict with the application but considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on oriently claim(s) or which is cried to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use; shibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION The standard of the same patent family "I alter document published siter the international filing date but invention or or priority gate and not in conflict with the application but can do understand the principle of theory underlying the invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document its combination being obvious to a person skilled in the sit. "4" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be con	1		G	rowth Factor Requirements, Pa	1ges 565-576, see	
issued 1989, G.D. Shipley, et al., Normal Human Keratinocytes and Fibroblasts in Serum-Free Medium Is Stimulated by Acidic and Basic Fibroblast Growth Factor, pages 511-518, gee entire document. *Special categories of cited documents: 10 *A document defining the general state of the art which is not considered to be of particular relevance *E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use; exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION	1					
issued 1989, G.D. Shipley, et al., Normal Human Keratinocytes and Fibroblasts in Serum-Free Medium Is Stimulated by Acidic and Basic Fibroblast Growth Factor, pages 511-518, gee entire document. *Special categories of cited documents: 10 *A document defining the general state of the art which is not considered to be of particular relevance *E earlier document but published on or after the international filing date "I document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use; exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION	- 1		,	ournel of Cellular Physiology,	Volume 138,	9-14
Normal Ruman Keratinocytes and by Acidic and Serum-Free Medium Is Stimulated by Acidic and Basic Fibroblast Growth Factor, "pages 511-518, see entire document." *Special categories of cited documents: 10 *A" document defining the general state of the art which is not considered to be of particular relevance *E" earlier document but published on or after the international filing date "L" document which may throw doubts on griority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use; exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION	-	Ā	1 .	coo c n Shinley, et s	BI GIDACH OF	15-22
*Special categories of cited documents: 10 *A" document defining the general state of the art which is not considered to be of particular relevance iffling date filling date. *E" earlier document but published on or after the international filing date. *L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other searcal reason (as specified) *O" document referring to an oral disclosure, use; exhibition or other means *P" document published prior to the international filing date but later than the priority date claimed *IV. CERTIFICATION *T" later document oublished siter the international filing date or or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention. *"" **T" later document oublished siter the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention. *"" **T" later document oublished siter the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the cited to understand the principle or theory underlying the cited to understand the principle or theory underlying the cited to understand the principle or theory underlying the cited to understand the principle or theory underlying the cited to understand the principle or theory underlying the cited to understand the principle or theory underlying the cited to understand the principle or theory underlying the cited to understand the principle or theory underlying the cited to understand the principle or theory underlying the cited to understand the principle or theory underlying the cited to understand the principle or theory underlying the cited to understand the principle or theory underlying the cited to understand the principle or theory underlying the cited to understand the principle or theory underlying	-	Y	N	ormal Human Keratinocytes and	d by Acidic and	
**T" later document published siter the international filing date or priority claims or considered to be of particular relevance. "L" document which may throw doubts on priority claims or which is cited to establish the publication date of which is cited to establish the publication date of which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use; exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION "T" later document published siter the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document such combined with one or more other such documents, such combination being obvious to a person skilled in the art. "a" document member of the same patent lamity	- 1		9	erum-Free negrum to Strands	, " pages 511-518,	
*T" later document oublished siter the international filing date or priority date and not in conflict with the application but considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cried to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use; exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "V" document is combined with one or more other such document is combined wi	-			ee entire document.		
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on griority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use; exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION	- 1		l .			
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on griority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use; exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION	- [ŀ			
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on griority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use; exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION	- 1		1		•	·
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on griority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use; exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION						
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on griority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use; exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION				_		•
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on griority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use; exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION	-				HTT later decument authinhed efter	the international filing date
considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cried to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use; exhibition or other means. "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION		• Spec	ial catego	pries of cited documents: 10		
filing date "L" document which may throw doubts on priority claim(s) or which is cried to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use; exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION "Cannot be considered novel of cannot be considered novel or cannot be co		cc	pasidered	10 pe of battichist televance	INVENTION	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use; exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION		"E" eq	priver docu	iment but published on or after the international	cannot be considered nover	or cannot be considered to
citation or other special reason (as specified) "O" document referring to an oral disclosure, use; exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION cannot be considered to involve an inverte an inverte and document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document member of the same patent family				which may throw doubts on priority claim(s) or	involve an inventive step	see the claimed invention
other means "P" document published prior to the international filing date but later than the priority date claimed IV. CERTIFICATION ments, such combination being defined in the art. "A" document member of the same patent family		Ci	tation of	other special reason (as specified)	Cannot be considered to theoly	or more other such docu-
"2" document published prior to the international filing date but later than the priority date claimed "2" document member of the same patent family IV. CERTIFICATION		G.	ther mear	15	ments, such combination being	obvious to a person skilled
IV. CERTIFICATION	- 1	-P- A	ACUMBOL:	published prior to the international filing date but	"&" document member of the same	patent family
	- }					
	-				Date of Mailing of this International	Search Report
agnrc 1991	1	2710 VI	• •	,	26 nfc 199	
13 DECEMBER 1991 ZOBEC 133	1		13 DI	ECEMBER 1991	WAR BLO 100	1 - MIH
International Searching Authority Signature of Authorized Officer Diane Moffett		Internat	ional Sea	rching Authority	Signature of Ammorized Unicer	none Willen
RO/US Jane Williams	ł		RU/116		Jane Williams	br.

Form PCT//SA/210 (second sheet) (Rev.11-87)

dota ,	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim
· Acià.	Chairen or Document, who more appropriate, of the relevant passages	
Y	Growth Factors and Other Aspects of Wound Healing: Biological and Clinical Implications, published 1988 by Alan R. Liss, Inc. (New York), G.G. Nemeth et al. pages 1-17, see entire document.	2-14 16-22
Y Y	Journal of Surgical Research, Volume 43, issued 1987, A. Buckley et al., *Epidermal Growth Factor Increases Granulation Tissue Formation Dose Dependently, * pages 322-328, see entire document.	<u>9-14</u> 16-22
YY	International Journal of Tissue Reactivity, Volume X, Number 6. issued 1988, G.R. Grotendorst, "Growth Factors as Regulators of Wound Repair," pages 337-344, see entire document.	8-14 16-22
Y Y	Proceedings of the National Academy of Sciences, Volume 85, issued March 1988. M. Eisinger et al., "Growth Regulation of Skin Cells by Epidermal Cell-Derived Factors: Implications for Wound Heeling," pages 1937-1941, see entire document.	8-14 16-22
Y	Tissue Culture Association 41st Annual Meeting, Houston TX, June 10-13, 1990, Annal Meeting Abstracts, issued 1990, G.D. Shipley., "Culture of Human Cells in Optimized Media," page 24A, see entire document.	8-18
Y	US, A, 4,423,145 (STAMPFER et al.) 27 December 1983, see entire document.	15
i		
	•	
		٠
	*	